Highline Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Highline Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-607,021	Closed	-$52M	–	29
2019 Q2	$52M	Sell	607,021 -459,228	-43%	-$39.3M	3.8%	12
2019 Q1	$94.7M	Buy	1,066,249 +53,130	+5%	+$4.92M	5.95%	4
2018 Q4	$86.3M	Sell	1,013,119 -273,831	-21%	-$26M	5.78%	7
2018 Q3	$125M	Sell	1,286,950 -32,500	-2%	-$3.24M	5.77%	6
2018 Q2	$124M	Buy	1,319,450 +45,550	+4%	+$3.99M	4.16%	6
2018 Q1	$103M	Buy	+1,273,900	New	+$109M	3.52%	12

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Highline Capital Management's BMRN Position: Q3 2019 in Review

Highline Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 607,021 shares — an estimated $52M sold.

Highline Capital Management first reported a position in BMRN in Q1 2018 and held it in 6 quarters. The position peaked at $125M in Q3 2018. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Highline Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Highline Capital Management sold 607,021 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $52M.
Highline Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Highline Capital Management's BioMarin Pharmaceuticals position peaked at $125M in Q3 2018.
436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Highline Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.